Oral absorption of propiverine solution and of the immediate and extended release dosage forms: Influence of regioselective intestinal elimination

European Journal of Clinical Pharmacology

Volumn 64, Issue 11, 2008, Pages 1085-1092

  May, Karen ^a   Giessmann, Thomas ^a   Wegner, Danilo ^a   Oertel, Reinhard ^b   Modess, Christiane ^a   Oswald, Stefan ^a   Braeter, Manfred ^c   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Dosage form; Efflux transport; Intestinal metabolism; Propiverine

Indexed keywords

CYTOCHROME P450; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPIVERINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZILATES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTESTINES; MALE; MUSCARINIC ANTAGONISTS; SOLUTIONS;

EID: 55349101603     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0528-0     Document Type: Article

References (34)

1. H Madersbacher G Murtz 2001 Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic) World J Urol 19 324 335
2. MC Michel SS Hegde 2006 Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374 79 85
3. M Wuest J Hecht T Christ 2005 Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction Br J Pharmacol 145 608 619
4. M Wuest A Weiss M Waelbroeck 2006 Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction Naunyn Schmiedebergs Arch Pharmacol 374 87 97
5. H Madersbacher M Halaska R Voigt 1999 A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence BJU Int 84 646 651
6. M Stohrer H Madersbacher R Richter 1999 Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia-a double-blind, placebo-controlled clinical trial Spinal Cord 37 196 200
7. P Abrams L Cardozo C Chapple 2006 Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome Int J Urol 13 692 698
8. M Stohrer G Murtz G Kramer 2007 Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double-blind, multicenter clinical study Eur Urol 51 235 242
9. KO Haustein G Huller 1988 On the pharmacokinetics and metabolism of propiverine in man Eur J Drug Metab Pharmacokinet 13 81 90
10. G Huller KO Haustein S Scheithauer 1988 Studies on the metabolic pattern of propiverine in urine after single administration Pharmazie 43 91 95
11. A Wengler T Schneider M Zschiesche 1988 Studies on the metabolism of the bladder spasmolytic, propiverin (mictonorm) in humans Pharmazie 43 652 653
12. W Siegmund M Nigussie K Tilahun 1990 Anticholinergic properties of propiverine and its metabolites Pharmazie 45 67 68
13. T Giessmann K May KU Moritz 2004 Disposition of propiverine and its metabolites is influenced by MRP2 Naunyn-Schmiedebergs Arch Pharmacol 369 R156
14. Y Kugimiya K Hanoaka Y Inada 1990 Phase I study of propiverine- hydrochloride. The first report. Single oral dosing study Jpn J Clin Pharmacol Ther 21 555 565
15. MA Siddiqui CM Perry LJ Scott 2004 Oxybutynin extended-release: a review of its use in the management of overactive bladder Drugs 64 885 912
16. P van Kerrebroeck K Kreder U Jonas 2001 Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 414 421
17. S Mouly MF Paine 2003 P-glycoprotein increases from proximal to distal regions of human small intestine Pharm Res 20 1595 1599
18. C Zimmermann H Gutmann P Hruz 2005 Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 MRNA expression along the human intestinal tract Drug Metab Dispos 33 219 224
19. G Englund F Rorsman A Ronnblom 2006 Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with caco-2 cells Eur J Pharm Sci 29 269 277
20. T Nakamura T Sakaeda N Ohmoto 2002 Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-MRNA levels in caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas Drug Metab Dispos 30 4 6
21. QY Zhang D Dunbar A Ostrowska 1999 Characterization of human small intestinal cytochromes P-450 Drug Metab Dispos 27 804 809
22. MF Paine M Khalighi JM Fisher 1997 Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1552 1562
23. R Oertel K Richter J Fauler 2002 Increasing sample throughput in pharmacological studies by using dual-column liquid chromatography with tandem mass spectrometry J Chromatogr A 948 187 192
24. Oertel R, Kilian B, Siegmund W et al (2006) Determination of propiverine and its metabolites in rat samples by liquid chromatography-tandem mass spectrometry. J Chromatogr A
25. K Richter S Scheithauer D Thummler 1998 High-performance liquid chromatographic determination of propiverine and its N-oxide in human serum J Chromatogr B Biomed Sci Appl 708 325 329
26. JK Aronson HJ Dengler L Dettli 1988 Standardization of symbols in clinical pharmacology Eur J Clin Pharmacol 35 1 7
27. ES Rovner AJ Wein 2002 Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review Eur Urol 41 6 14
28. SK Gupta G Sathyan 1999 Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin J Clin Pharmacol 39 289 296
29. B Olsson J Szamosi 2001 Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine Clin Pharmacokinet 40 227 235
30. CA Massad BA Kogan FE Trigo-Rocha 1992 The pharmacokinetics of intravesical and oral oxybutynin chloride J Urol 148 595 597
31. LM Chan S Lowes BH Hirst 2004 The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability Eur J Pharm Sci 21 25 51
32. CG Dietrich A Geier RPJO Elferink 2003 ABC of oral bioavailability: transporters as gatekeepers in the gut Gut 52 1788 1795
33. M Takano R Yumoto T Murakami 2006 Expression and function of efflux drug transporters in the intestine Pharmacol Ther 109 137 161
34. KP Junemann E Hessdorfer I Unamba-Oparah 2006 Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder Urol Int 77 334 339